Heinz Lubenau

XM02 is superior to placebo and equivalent to Neupogen™ in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel/doxorubicin chemotherapy

Auro del Giglio, Alexandru Eniu, Doina Elena Ganea-Motan et al. · BMC Cancer · 2008 · 105 citations · Full text

XM02, the First Biosimilar G-CSF, is Safe and Effective in Reducing the Duration of Severe Neutropenia and Incidence of Febrile Neutropenia in Patients with Small Cell or Non-small Cell Lung Cancer Receiving Platinum-Based Chemotherapy

U. Gatzemeier, Tudor–Eliade Ciuleanu, Mircea Dediu et al. · Journal of Thoracic Oncology · 2009 · 87 citations · Full text

Translational Medicine, Malignant Disease, Medicine +11

XM02, the first granulocyte colony-stimulating factor biosimilar, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with non-Hodgkin lymphoma receiving chemotherapy

Andreas Engert, Laimonas Griškevičius, Y. Zyuzgin et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2009 · 75 citations

Anti-angiogenic activity of VXM01, an oral T-cell vaccine against VEGF receptor 2, in patients with advanced pancreatic cancer: A randomized, placebo-controlled, phase 1 trial

Friedrich H. Schmitz-Winnenthal, Nicolas Hohmann, Andreas G. Niethammer et al. · OncoImmunology · 2015 · 72 citations · Full text

A phase 1 trial extension to assess immunologic efficacy and safety of prime-boost vaccination with VXM01, an oral T cell vaccine against VEGFR2, in patients with advanced pancreatic cancer

Friedrich H. Schmitz-Winnenthal, Nicolas Hohmann, Thomas Schmidt et al. · OncoImmunology · 2017 · 71 citations · Full text